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Abstract: Currently, there is no cure for chronic obstructive pulmonary disease (COPD). 
The limited efficacy of current therapies for COPD indicates a pressing need to develop new 
treatments to prevent the progression of the disease, which consumes a significant amount of 
health care resources and is an important cause of mortality worldwide. Current national and 
international guidelines for the management of stable COPD patients recommend the use of 
inhaled long-acting bronchodilators, inhaled corticosteroids, and their combination for mainte-
nance treatment of moderate to severe stable COPD. Once-daily fluticasone furoate/vilanterol 
dry powder inhaler combination therapy has recently been approved by the US Food and Drug 
Administration and the European Medicines Agency as a new regular treatment for patients with 
stable COPD. Fluticasone furoate/vilanterol dry powder inhaler combination therapy has been 
shown to be effective in many controlled clinical trials involving thousands of patients in the 
regular treatment of stable COPD. This is the first once-daily combination of ultra-long-acting 
inhaled β
2
-agonists and inhaled glucocorticoids that is available for the treatment of stable 
COPD and has great potential to improve compliance to long-term regular inhaled therapy and 
hence to improve the natural history and prognosis of COPD patients.
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Introduction
The limited efficacy of current therapies for chronic obstructive pulmonary disease 
(COPD) indicates a pressing need to develop new treatments to prevent the progres-
sion of the disease, which consumes a significant amount of health care resources and 
is an important cause of mortality worldwide.
Current national and international guidelines for the management of stable COPD 
patients recommend the use of inhaled long-acting bronchodilators, inhaled corti-
costeroids (ICSs), and their combination for maintenance treatment of moderate to 
severe stable COPD.1,2
Regular treatment of stable COPD patients with long-acting inhaled β
2
-agonists 
(LABAs) alone produces modest increases in lung function with varying effects on 
health-related quality of life and reduction in symptoms. However, it is also associated 
with a consistent reduction in exacerbations, which may help people with COPD who 
suffer frequent deterioration of symptoms prompting health care utilization.3 In addi-
tion, the evidence is equivocal as to whether or not tiotropium offers greater benefit 
than LABAs in improving quality of life. Symptom improvement and changes in lung 
function are similar between the treatment groups. Tiotropium is more effective than 
LABAs in preventing COPD exacerbations and disease-related hospitalizations, but 
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there are no statistical differences between groups in overall 
hospitalization rates or mortality during the study periods.4
A Cochrane review of the role of regular long-term 
treatment with ICSs alone versus placebo in patients with 
stable COPD has concluded that it reduces significantly the 
mean rate of exacerbations and the rate of decline of quality 
of life but not forced expiratory volume in 1 second (FEV
1
) 
decline or mortality rates.5 ICS treatment is also associated 
with side effects (such as increased risk of oropharyngeal 
candidiasis, hoarseness, and pneumonia).5
When the clinical efficacy of LABAs alone versus ICSs 
alone has been compared it has been shown that these two 
therapies confer similar benefits across the majority of 
outcomes, including the frequency of exacerbations and 
mortality. Use of LABAs appears to confer a small addi-
tional benefit in terms of improvements in lung function 
compared with ICSs. On the other hand, ICSs have a small 
advantage over LABAs in terms of health-related quality 
of life but are also associated with a dose-related increased 
risk of pneumonia.6,7
Several large controlled clinical trials of inhaled com-
bination therapy with ICSs and LABAs in a single device 
in stable COPD have shown that this combination therapy 
is well tolerated and produces a modest but statistically 
significant reduction in the number of severe exacerbations 
and improvement in FEV
1
, quality of life, and respiratory 
symptoms in stable COPD patients, with no greater risk of 
side effects than that with use of either component alone. 
Increased risk of pneumonia is a concern; however, this did 
not translate into increased exacerbations, hospitalizations, 
or deaths.8
In addition, the Towards a Revolution in COPD Health 
(TORCH) study showed a 17% relative reduction in mortal-
ity over 3 years for patients receiving salmeterol (SAL)/
fluticasone propionate (FP), although this just failed to reach 
significance.9 Furthermore, systematic reviews of the litera-
ture suggest that a combination of ICSs and LABAs reduces 
mortality by approximately 20%, whereas neither tiotropium 
nor LABA by itself modifies all-cause mortality in COPD.10 
ICSs have been found to be associated with a reduction in 
mortality rate when compared with LABAs among patients 
with COPD.11 However, ICS/LABA combination therapy 
did not provide any additional benefit on mortality when 
compared with ICS monotherapy.12
A recent Cochrane review of the field has concluded 
that combined inhaler therapy led to around a quarter fewer 
COPD exacerbations than were seen with placebo. Current 
evidence does not suggest any major differences between 
inhalers in terms of effects; however, nor is the evidence 
strong enough to demonstrate that all these combinations 
are equivalent.8
The development of improved LABAs has focused on 
once-daily agents (termed ultra-LABAs [ULABAs]) like 
indacaterol and olodaterol, which have been proved to be 
more effective compared with twice-daily dosing with a 
good safety profile.13–17
Just as for LABAs, the development of improved ICSs 
has focused on once-daily agents to allow regular treatment 
of patients with stable COPD with once-daily dual-therapy 
combined inhalers.18
There are many new ULABAs and once-daily ICSs 
under preclinical or early clinical development.13–18 We will 
review here the preclinical and clinical profile of once-daily 
fluticasone furoate/vilanterol trifenatate (FF/VI) dry powder 
inhaler (DPI) combination therapy, which has recently been 
approved by the US Food and Drug Administration and the 
European Medicines Agency as a new regular treatment for 
patients with stable COPD.19,20
Pharmacodynamics of fluticasone 
furoate and vilanterol
Fluticasone furoate
The anti-inflammatory actions of glucocorticoids occur 
through activation of glucocorticoid receptors (GRs), which 
are members of the nuclear hormone receptors family and 
are found in the cytoplasm of virtually all cells.21,22 GRs are 
predominantly localized to the airway epithelium, alveolar 
macrophages, and endothelium, which are therefore probably 
important sites for the anti-inflammatory action of glucocor-
ticoids, especially those delivered by the inhaled route. The 
GR gene encodes many protein isoforms. A cytoplasmic 
alpha form (GRα), which binds hormone, translocates to 
the nucleus and regulates gene transcription, and a nuclear 
localized beta isoform (GRβ), which is much less abundant 
in the cells, does not bind known ligands and, despite ongo-
ing controversy, appears to attenuate GRα action when 
overexpressed.23,24 Glucocorticoids bind to and activate 
the cytosolic GR, which then translocates into the nucleus. 
Within the nucleus, GRs can act as a positive transcription 
factor by forming homodimers of two GR subunits, which 
bind to specific DNA elements (glucocorticoid response ele-
ments) in the promoter regions of glucocorticoid-responsive 
genes. Several genes are upregulated by glucocorticoids, 
including the β
2
-adrenergic receptor (β
2
-AR). However, in 
inflammation, the major role of glucocorticoids appears to 
be gene repression.21,22 The major anti-inflammatory action 
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of glucocorticoids is the repression of the proinflammatory 
actions of nuclear factor kappaB (NF-κB), resulting in a 
reduction in inflammatory gene transcription. Functionally, 
glucorticoids act by suppressing airway hyper-responsiveness, 
reducing airway edema and the infiltration of inflammatory 
cells from the blood to the airway and thereby reducing the 
lower airway inflammatory response.21
FF (formerly drug code GW685698) is a novel enhanced-
affinity synthetic trifluorinated glucocorticoid.25 X-ray 
crystallography comparison studies of its structure with that 
of dexamethasone and FP have demonstrated that the 17-α 
furoate ester occupies more fully the lipophilic 17-α pocket 
on the ligand binding domain of GR, and this may account 
for the enhanced GR binding of FF.26
In fact, in vitro FF has a fast association and a slow dis-
sociation from the GR, resulting in a relative receptor affinity 
(RRA) of 30 with reference to dexamethasone (RRA =1), 
which is superior to budesonide (RRA =8), ciclesonide’s 
active metabolite des-ciclesonide (RRA =12), FP (RRA =18), 
and mometasone furoate (RRA =22).27
Furthermore, both FP and FF have pronounced retention 
(without instability or chemical modification) in human lung 
tissue in vitro, like budesonide, whereas mometasone furoate 
has the lowest human lung tissue binding.27
In addition, FF has very potent glucocorticoid activity in 
several key pathways downstream of the GR, including the 
transrepression NF-κB pathway, the transactivation of the 
glucocorticoid response element pathway, and the inhibition 
of the proinflammatory cytokine tumor necrosis factor-α, 
and, unlike FP, FF action is resistant to oxidative stress.25,28
FF has similar or slightly higher potency to FP and is 
twofold to ninefold more potent than budesonide in inhibit-
ing inflammatory cytokine production in epithelial cell lines, 
primary bronchial epithelial cells, and a monocytic cell line 
(U937). In addition, FF has superior effects to FP in periph-
eral blood mononuclear cells from patients with COPD and 
also in U937 cells or primary bronchial epithelial cells under 
conditions of oxidative stress.28
FF has a longer duration of action in several cell systems 
compared with FP and budesonide, resulting in prolonged 
action and 24-hour coverage with once-daily dosing.28
The activated GR is detectable in the nucleus of FF-
treated epithelial cell lines for at least 30 hours, and FF has 
a longer duration of action than FP in inhibiting activation 
of proinflammatory transcription factors such as NF-κB and 
activator protein 1.28
In vivo in healthy male subjects, in comparison with 
inhaled FP, inhaled FF (independent of its formulation) 
demonstrated prolonged absorption from the lung into the 
systemic circulation, indicating a longer lung retention time 
and suggesting the potential for maintained efficacy with 
once-daily administration.29,30
vilanterol
β
2
-agonists are effective bronchodilators, due primarily to 
their ability to relax airway smooth muscle.13,15 In addition 
to prolonged bronchodilation, LABAs exert other β
2
-agonist-
mediated effects in vitro that may be of clinical relevance 
in patients with COPD. These include inhibition of airway 
smooth muscle cell proliferation and inflammatory mediator 
release, as well as non-smooth muscle effects, such as stimu-
lation of mucociliary transport, reduction of the bronchial 
epithelial damage caused by bacterial toxins, and attenuation 
of neutrophil recruitment and activation.31
Inhaled β
2
-agonists target β
2
-ARs expressed in high 
numbers (3–4×104 per cell) on the airway smooth muscle 
cells of the large and small airways (their number increases 
with increasing airway generation) and also on other impor-
tant target cells, including lower airway epithelium (with the 
highest levels expressed on the type 1 and 2 alveolar cells) and 
submucosal glands, vascular smooth muscle, macrophages, 
neutrophils, lymphocytes, eosinophils, mast cells, and the 
endothelium of the postcapillary venules.13,32
Ligand binding to the β
2
-AR results in activation of recep-
tor-associated G-stimulatory proteins and enhanced coupling 
with the enzyme adenylyl cyclase, which leads to increased 
production of cyclic adenosine monophosphate (cAMP), 
leading to relaxation of airway smooth muscle.15,21,22,33
β
2
-agonists may also influence gene transcription. cAMP 
causes translocation of the catalytic subunit of the protein 
kinase A to the nucleus, where it phosphorylates and activates 
the transcription factor cAMP response element binding pro-
tein, enhancing its DNA-binding and transactivating activity. 
Activation of the β
2
-AR can also lead to stimulation of the 
extracellular signal-regulated kinases/mitogen-activated 
protein kinases (MAPK) pathway. Activation of the β
2
-AR 
can also induce p38 MAPK activation in a manner similar to 
that seen with extracellular signal-regulated kinases/MAPK 
activation.15,21,22,33
β
2
-agonists may also potentiate in the lower airways 
of patients with COPD the molecular mechanism of glu-
cocorticoid actions, with increased nuclear localization of 
GRs and additive or sometimes synergistic suppression 
of inflammatory mediator release.34 Activation of CAAT/
enhancer-binding protein by inhaled long-acting β
2
-agonists 
in airway smooth muscle cells has been proposed to account, 
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at least in part, for the enhanced effect of this combination 
treatment in asthmatic patients.35
Vilanterol trifenatate (formerly named compound 13f.
triphenylacetate or GSK-642444) is a novel ULABA that 
has been synthesized by incorporation of an oxygen atom at 
the homobenzylic position of the right-hand-side phenyl ring 
of (R)-SAL and has suitable chemical properties for inhaled 
administration.36
The affinity of VI for the β
2
-AR is higher than formot-
erol, indacaterol, and olodaterol but comparable with that of 
SAL.13,37 VI is a highly lipophilic molecule partitioning into 
cell membrane and forming depots of drug in the cell mem-
brane, but it is not possible to rule out that vilanterol binds 
directly to an anchored binding site within the β
2
-AR.37
In functional activity studies, VI has a similar selectiv-
ity profile as SAL for β
2
-AR over β
1
-AR and β
3
-AR, but 
a significantly improved selectivity profile than albuterol 
(salbutamol), formoterol, and indacaterol, decreasing the 
risk of untoward effects due to the stimulation of the other 
β-ARs.13,37
VI also has a level of intrinsic efficacy (an agonist of 
high intrinsic efficacy might offer advantages in clinical 
effectiveness over a weak partial agonist)38 comparable 
with indacaterol but significantly greater than that of SAL. 
In in vitro cell-based studies, VI has a persistence of action 
comparable with indacaterol and longer than formoterol 
and SAL.13,37
VI has a rapid turnover because it is rapidly metabolized 
by the human liver microsomes.36 VI, formoterol, and inda-
caterol have a more rapid onset of activity compared with 
SAL. In human airways preconstricted with histamine, VI has 
a significantly faster onset of action (3.1 minutes) compared 
with SAL (8.3 minutes).13 In vitro in human airways, VI has 
longer duration of action than SAL, exhibiting a significant 
level of bronchodilation 22 hours after treatment.37
Together, this results in VI having in vivo a dose-
 dependent rapid bronchodilation in healthy subjects and 
in patients with stable COPD, which is maintained over 
24 hours.39,40 In asthmatic patients there is no bronchodilation 
advantage over a 24-hour period of vilanterol twice-daily 
versus once-daily dosing for the same total daily dose.41
Pharmacokinetics of fluticasone 
furoate and vilanterol
Following intranasal administration of FF, most of the 
swallowed dose undergoes incomplete absorption and 
extensive first-pass metabolism in the liver by the hepatic 
cytochrome P450 isozyme CYP3A4, resulting in negligible 
systemic exposure (oral bioavailability is ,0.5%). At the 
highest recommended intranasal dosage, plasma concentra-
tions of FF are typically not quantifiable, despite the use 
of a highly sensitive high-performance liquid chromato-
graphy–mass spectrometry assay in subjects of all ages.42 
Concomitant administration of strong CYP3A4 inhibitors 
like ketoconazole increases the plasma concentrations of 
both FF and VI.43
Using pharmacokinetic studies performed in normal 
subjects and asthmatic patients, the models predict that an 
FF area under the concentration–time curve over 24 hours 
postdose of 1,000 pg ⋅ hour/mL would be required to reduce 
24-hour serum cortisol or 24-hour urine cortisol excretion 
by 20% and 17%, respectively.44
FF inhalation is associated with reduced serum cortisol 
in patients with moderate hepatic impairment, suggesting 
that caution should be exercised when prescribing FF/VI 
in patients with moderate or severe hepatic impairment, 
due to a risk for unwanted systemic glucocorticoid effects 
associated with increased FF systemic exposure.45 However, 
hepatic function impairment has no effect on VI systemic 
exposure.45
FF is not detectable (,1%) in the urine of healthy sub-
jects following intranasal dosing, and severe renal function 
impairment has no clinically relevant effects on the phar-
macokinetic or pharmacodynamic properties or tolerability 
of FF/VI.42,45
Clinical efficacy of fluticasone 
furoate/vilanterol dry powder 
inhaler combination therapy versus 
placebo in the regular treatment  
of stable COPD
Effect on lung function, symptoms,  
and exercise tolerance
Given once daily to patients with moderate to severe stable 
COPD, inhaled FF/VI combination improved trough FEV
1
 
by more than 200 mL in two 28-day trials versus placebo.46,47 
However, a more modest increase (100–130 mL) was seen 
in two longer 12 to 28-week trials.48–51 The regular treat-
ment of stable COPD patients with FF/VI combination 
decreases their symptoms, particularly dyspnea, in two 
12 to 28-week trials, but there are no published studies on 
the effect of this therapy on exercise tolerance of stable 
patients with COPD.46–48,50–52
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Prevention of COPD exacerbations, 
accelerated Fev1 decline, long-term 
compliance to inhaled therapy,  
and mortality
In the two longest trials of 1-year duration involving more 
than 3,000 patients with stable moderate to severe COPD 
randomized to FF/VI or VI alone, the treatment with FF/VI 
was associated with a slight (27%) but significant decrease 
(0.81 versus [vs] 1.11) in the yearly rate of moderate plus 
severe COPD exacerbations, the time to first moderate 
or severe exacerbation, and the frequency of exacerba-
tions requiring systemic glucocorticoids. There was no 
difference in the rate of COPD exacerbations requiring 
hospitalization.52
The Study to Understand Mortality and Morbidity in 
COPD (SUMMIT) aims to determine the impact of FF/VI 
combination and the individual components on the survival 
of patients with moderate stable COPD and either a his-
tory of cardiovascular disease or those at increased risk for 
cardiovascular disease. SUMMIT is a multicentre, random-
ized, double-blind, parallel-group, placebo-controlled trial 
of 16,000 patients with moderate stable COPD randomly 
assigned to once-daily treatment with FF/VI (100/25 µg), FF 
(100 µg), VI (25 µg), or matched placebo. Mortality is the pri-
mary end point. The study is an event-driven trial  powered by 
the comparison of FF/VI with placebo. Secondary end points 
are decline in FEV
1
 and effect on a composite cardiovascular 
end point.53 The study is underway, and it is estimated that 
it will be completed by July 2015 (http://clinicaltrials.gov/
show/NCT01313676).
There are no published studies on the role of the effect 
of regular treatment of patients with stable COPD with 
FF/VI combination in the prevention of their accelerated 
FEV
1
 decline and/or in their long-term compliance to the 
inhaled therapy.
Clinical efficacy of fluticasone 
furoate/vilanterol dry powder 
inhaler vs fluticasone propionate/
salmeterol combination therapy  
in the regular treatment  
of stable COPD
There are efficacy data comparing FF/VI with FP/SAL com-
bination in the treatment of stable COPD. In one 12-week 
trial, weighted mean FEV
1
 (mean 130 mL) was greater, 
and time to 100 mL improvement was shorter (median 
16 minutes) with FF/VI than with FP/SAL (weighted mean 
108 mL; median 28 minutes). Health status (St George’s 
Respiratory Questionnaire total score) improved in both 
groups (FF/VI −4.3 units; FP/SAL −3.0 units), but differences 
between treatments were not statistically significant.48
Anti-inflammatory effect  
of fluticasone furoate/vilanterol 
dry powder inhaler combination 
therapy in the regular treatment  
of stable COPD
Airway biopsy studies are required to evaluate whether FF/
VI has a significant in vivo anti-inflammatory activity in 
the lower airways in addition to its known bronchodilator 
properties.
Side effects and cost-effectiveness 
of fluticasone furoate/vilanterol 
dry powder inhaler combination 
therapy in the regular treatment  
of stable COPD
Unlike other LABAs and ULABAs, vilanterol is not available 
as a single agent and is marketed only in a fixed combina-
tion with 100 µg of FF at a dosage of 25 µg of vilanterol 
administered in a new DPI (Ellipta™; GlaxoSmithKline plc., 
Brentford, UK) incorporating a dose counter. In one study 
this new device was associated with high patient satisfaction 
and was preferred to other DPI and metered dose inhalers, 
according to an interview of patients with COPD, and this 
may increase adherence to therapy in COPD.54
Like other inhaled β
2
-agonists, VI may cause clinically 
significant cardiovascular effects (including an increase of 
the pulse rate and of the systemic arterial blood pressure and 
prolongation of the QT interval of the electrocardiogram 
[ECG] corrected for the heart rate) and therefore must be 
used with caution during acute coronary syndromes and in 
patients with cardiac arrhythmia and/or chronic heart failure. 
However, the safety of single and repeat VI doses up to 50 µg 
has been established in healthy subjects with no clinically 
significant abnormalities in vital signs, 12-lead ECG, Holter 
ECG, blood glucose or potassium, and corrected QT (QTc) 
observed,55,56 but some prolongation of the QTc was seen 
following the 100 µg VI dose after single and repeat doses 
in healthy subjects.40,56
In healthy Japanese subjects, no safety concerns were 
found following single or repeat dosing of FF, VI, and 
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FF/VI. Systemic exposure to FF and VI increases in a 
dose-dependent manner. In these subjects, serum cortisol 
level is suppressed by 97% after 7 days of repeat administra-
tion of FF at a dose of 800 µg.57
The regular treatment of the patients with stable COPD 
with FF/VI DPI combination is usually well tolerated. The 
adverse events reported most often in the short- and long-term 
clinical studies of FF/VI DPI combination therapy versus 
placebo in the regular treatment of stable COPD include 
nasopharyngitis (9%), upper respiratory tract infection (7%), 
headache (7%), and dysphonia and oropharyngeal candidi-
asis (5%).46–52,58 However, in the two longest trials of 1 year 
duration, both pneumonia and bone fractures were seen 
more frequently with an FF/VI combination therapy than 
with VI alone.52 Although the rate of pneumonia roughly 
doubled in the groups taking FF, this increase is similar to 
the increased pneumonia risk described previously with FP 
and in some studies of budesonide and mometasone.52 In 
addition, the incidence of these events was very low com-
pared with the rate of COPD exacerbations, which was ten 
times higher. Eight deaths from pneumonia were observed 
in the FF/VI combination group compared with none in the 
VI only group.52
There are safety data showing that the short-term treat-
ment of stable COPD patients with FF/VI versus FP/SAL 
combination is equally well tolerated.48 The new FF/VI 
combination must not be used in the treatment of COPD 
exacerbations or for the treatment of asthmatic patients.
There is no formal cost-effectiveness analysis  published 
on the use of an FF/VI DPI combination versus other 
combinations in the regular treatment of patients with 
stable COPD.
Conclusion
The actual effectiveness achieved in clinical practice with 
any COPD therapies depends on patients’ inhaler technique, 
adherence, and persistence.59 Low adherence to maintenance 
inhaled therapy is common in COPD and is associated 
with worst prognosis,60 whereas improved adherence to 
regular treatment is associated with reduced rate of all-cause 
hospitalization.61 In general, frequent dosing and the use of 
multiple inhalers are associated with low adherence of the 
patients to long-term inhaled therapy in COPD.62,63 FF/VI 
DPI combination therapy has been shown effective in many 
controlled clinical trials involving thousands of patients 
in the regular treatment of stable COPD and has recently 
been approved for this indication by the US Food and Drug 
Administration and the European Medicines Agency. This 
is the first once-daily combination of ULABAs and inhaled 
glucocorticoids available for the treatment of stable COPD 
and has great potential to improve adherence to long-term 
regular inhaled therapy and hence to improve the natural 
history and prognosis of COPD patients.
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